Europe's largest venture round of the year doubles to more than $150m the amount raised by Immatics Biotechnologies since its launch.
Immatics Biotechnologies, a Germany-based kidney and anti-cancer drugs developer, has raised €53.8m ($75m), Europe’s largest venture round of the year and doubling the amount it has raised since its launch.
About half of the series C round came from Dievini Hopp Biotech, a local investment firm set up by a co-founder of Germany-based software company SAP, venture capital group Wellington Partners and other existing shareholders, including VC Vinci Capital’s Mona Lisa fund, which has Switzerland phone operator Swisscom as its…
